News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

News|Videos|July 3, 2024

Monitoring Patients With Mild/Moderate Multiple Sclerosis

The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.

Episodes in this series

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

How frequently should patients with mild to moderate MS be evaluated for disease activity and progression?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis

Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM

Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action

FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis

Pride Month 2026: Understanding Seizure Risk and Gender-Affirming Hormone Therapy